MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
DexCom Operating Income 2011-2026 | DXCM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 912 M | 600 M | 598 M | 391 M | 266 M | 300 M | 142 M | -186 M | -42.5 M | -63.9 M | -57.1 M | -21.5 M | -28.9 M | -55.7 M | -44.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 912 M | -186 M | 181 M |
Quarterly Operating Income DexCom
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 255 M | - | 213 M | 134 M | - | 152 M | 158 M | 101 M | - | 206 M | 128 M | 47.2 M | - | 148 M | 77 M | 41.3 M | - | 118 M | 101 M | 45.9 M | - | 94.1 M | 67.8 M | 33.6 M | - | 56 M | -800 K | -14.4 M | - | 13.9 M | -4.9 M | -30.7 M | - | -500 K | -13.6 M | -40.4 M | - | -18.5 M | -20.1 M | -19.2 M | - | -42.4 M | -3.6 M | -12.7 M | - | -5 M | -5.8 M | -12.3 M | - | -5.8 M | -9.9 M | -10.9 M | - | -17.3 M | -14.7 M | -15.4 M | - | -13.3 M | -7.39 M | -11.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 255 M | -42.4 M | 40.9 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.59 | 1.27 % | $ 2.12 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.6 | -3.61 % | $ 683 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.9 | -1.46 % | $ 451 M | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 117.53 | 4.77 % | $ 35.7 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 20.7 | -1.24 % | $ 1.1 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 139.07 | -0.22 % | $ 22.1 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 85.82 | -2.23 % | $ 5.79 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Medpace Holdings
MEDP
|
535 M | $ 430.32 | 3.19 % | $ 12.4 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.27 | 1.98 % | $ 2.01 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 18.74 | 2.85 % | $ 419 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 121.32 | 8.35 % | $ 10 B |  Irlanda |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.45 | 0.8 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
-68.3 M | $ 5.56 | -5.76 % | $ 329 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 185.39 | 7.58 % | $ 9.19 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 89.52 | -1.81 % | $ 11.2 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 5.03 | 1.82 % | $ 466 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.86 | -1.56 % | $ 1.13 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 466.76 | 0.9 % | $ 176 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.01 | 0.4 % | $ 8.89 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.0 | -0.2 % | $ 209 M | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.92 | 0.04 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 56.7 | 0.91 % | $ 3.39 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.19 | 1.16 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 257.14 | 1.64 % | $ 21.4 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 141.69 | -2.27 % | $ 6.63 B | USA |
 |
Natera
NTRA
|
-541 M | $ 206.77 | -2.26 % | $ 20.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.02 | -0.96 % | $ 180 M | China |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 190.84 | -0.34 % | $ 21.2 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 342.75 | 13.54 % | $ 20.4 B | USA |